Hitting the bull’s eye: targeting HMGA1 in cancer stem cells

References

• Dick JE. Stem cell concepts renew cancer research. Blood 112, 4793–4807 (2008).
   PubMed Web of Science ®Google Scholar
• McDermott SP, Wicha MS. Targeting breast cancer stem cells. Mol. Oncol. 4, 404–419 (2010).
   PubMed Web of Science ®Google Scholar
• Marjanovic ND, Weinberg RA, Chaffer CL. Cell Plasticity and Heterogeneity in Cancer. Clin. Chem. 59(1), 168–179 (2013).
   PubMed Web of Science ®Google Scholar
• Magee JA, Piskounova E, Morrison SJ. Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell 21, 283–296 (2012).
   PubMed Web of Science ®Google Scholar
• Koorstra JB, Hustinx SR, Offerhaus GJ, Maitra A. Pancreatic carcinogenesis. Pancreatol. 8(2), 110–125 (2008).
   PubMed Web of Science ®Google Scholar
• Hristov A, Cope L, Di Cello F et al. HMGA1 correlates with advanced tumor grade and decreased survival in pancreatic ductal adenocarcinoma. Mod. Pathol. 23, 98–104 (2010).
   PubMed Web of Science ®Google Scholar
• Gerlinger M, Rowan AJ, Horswell S et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366, 883–892 (2012).
   PubMed Web of Science ®Google Scholar
• Gerber JM, Smith DB, Ngwang Bet al.. Clinically relevant population of leukemic CD34+CD38-cells in acute myeloid leukemia. Blood 119(12) 3571– 3577 (2012).
   Google Scholar
• Ben-Porath MW, Thomson VJ, Carey Ret al.. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat. Genet. 40, 499–507 (2008).
   Google Scholar
• Shah SN, Kerr C, Cope L et al. HMGA1 reprograms somatic cells into pluripotent stem cells by inducing stem cell transcriptional networks. PLoS ONE 7(11), e48533 (2012).
   PubMed Web of Science ®Google Scholar
• Belton A, Gabrovsky A, Kyung Bae Y et al. HMGA1 induces intestinal polyposis in transgenic mice and drives tumor progression and stem cell properties in colon cancer cells. PLoS ONE 7(1), e30034 (2012).
   PubMed Web of Science ®Google Scholar
• Shah SN, Cope L, Poh W et al. HMGA1: a master regulator of tumor progression in triple negative breast cancer. PLoS ONE 8(5), e63419 (2013).
   PubMed Web of Science ®Google Scholar
• Reeves R, Beckerbauer L. HMGI/Y proteins: flexible regulators of transcription and chromatin structure. Biochim. Biophys. Acta 1519, 13–29 (2001).
   PubMed Web of Science ®Google Scholar
• Fusco A, Fedele M. Roles of HMGA proteins in cancer. Nat. Rev. Cancer 7, 899–910 (2007).
   PubMed Web of Science ®Google Scholar
• Resar LMS. High mobility group A1 gene: transforming inflammation into cancer? Cancer Res. 70(2), 436–439 (2010).
   PubMed Web of Science ®Google Scholar
• Johnson KR, Lehn DA, Elton TS, Barr PJ, Reeves R. Complete murine cDNA sequence, genomic structure, and tissue expression of the high mobility group protein HMG-I(Y). J. Biol. Chem. 263, 18338–18342 (1988).
   PubMed Web of Science ®Google Scholar
• Friedmann M, Holth LT, Zoghbi HY, Reeves R. Organization, inducible-expression and chromosome localization of the human HMG-I(Y) nonhistone protein gene. Nuc. Acids Res. 21, 4259–4267 (1993).
   PubMed Web of Science ®Google Scholar
• Pedulla ML, Treff NR, Resar LMS, Reeves R. Sequence and analysis of the murine Hmgiy (Hmga1) gene locus. Gene 271, 51–58 (2001).
   Google Scholar
• Lund T, Holtlund J, Fredriksen M, Laland SG. On the presence of two new high mobility group-like proteins in HeLa S3 cells. FEBS Lett. 152, 163–167 (1983).
   PubMed Web of Science ®Google Scholar
• Reeves R, Edberg DD, Li Y. Architectural transcription factor HMGI(Y) promotes tumor progression and mesenchymal transition of human epithelial cells. Mol. Cell Biol. 21, 575–594 (2001).
   PubMed Web of Science ®Google Scholar
• Martinez Hoyos J, Fedele M, Battista S et al. Identification of the genes up- and down-regulated by the high mobility group A1 (HMGA1) proteins: tissue specificity of the HMGA1-dependent gene regulation. Cancer Res. 64, 5728–5735 (2004).
   PubMed Web of Science ®Google Scholar
• Schuldenfrei A, Belton A, Kowalski J et al. HMGA1 drives inflammatory pathways, cell cycle progression, and embryonic stem cell genes during lymphoid tumorigenesis. BMC Genomics 12, 549 (2011).
   PubMed Web of Science ®Google Scholar
• Thanos D, Maniatis, T. The high mobility group protein HMG I(Y) is required for NF-kappa B-dependent virus induction of the human IFN-beta gene. Cell 71, 777–789 (1992).
   PubMed Web of Science ®Google Scholar
• Du W, Maniatis T. The high mobility group protein HMG I(Y) can stimulate or inhibit DNA binding of distinct transcription factor ATF-2 isoforms. Proc. Natl Acad. Sci. USA 91, 11318–11322 (1994).
   PubMed Web of Science ®Google Scholar
• Falvo JV, Thanos D, Maniatis T. Reversal of intrinsic DNA bends in the IFN beta gene enhancer by transcription factors and the architectural protein HMG I(Y). Cell 83, 1101–1111 (1995).
   PubMed Web of Science ®Google Scholar
• Thanos D, Maniatis T. Virus induction of human IFN beta gene expression requires the assembly of an enhanceosome. Cell 83, 1091–1100 (1995).
   PubMed Web of Science ®Google Scholar
• Munshi N, Agalioti T, Lomvardas S, Merika M, Chen G, Thanos D. Coordination of a transcriptional switch by HMGI(Y) acetylation. Science 293, 1133–1136. (2001).
   PubMed Web of Science ®Google Scholar
• Panne D, Maniatis T, Harrison SC. An atomic model of the interferon-beta enhanceosome. Cell 129, 1111–1123 (2007).
   PubMed Web of Science ®Google Scholar
• E Ford, D. Thanos. The transcriptional code of human IFN-β gene expression. Biochem. Biophy. Acta 1799, 328–336 (2010).
   PubMed Web of Science ®Google Scholar
• Saitoh Y, Laemmli UK. Metaphase chromosome structure: bands arise from a differential folding path of the highly AT-rich scaffold. Cell 76, 609–622 (1994).
   PubMed Web of Science ®Google Scholar
• Girard F, Bello B, Laemmli UK, Gehring WJ. (1998) In vivo analysis of scaffold-associated regions in Drosophila: a synthetic high-affinity SAR binding protein suppresses position effect variegation. EMBO J. 7, 2079–2085 (1998).
   Google Scholar
• Zhao K, Kas E, Gonzalez E., Laemmli UK. SAR-dependent mobilization of histone H1 by HMG-I/Y in vitro: HMG-I/Y is enriched in H1-depleted chromatin. EMBO J. 12, 3237–3247 (1993).
   PubMed Web of Science ®Google Scholar
• Strick R, Laemmli UK. SARs are cis DNA elements of chromosome dynamics: synthesis of a SAR repressor protein. Cell 83, 1137–1148 (1995).
   PubMed Web of Science ®Google Scholar
• Mirkovitch J, Mirault ME, Laemmli UK. Organization of the higher-order chromatin loop: specific DNA attachment sites on nuclear scaffold. Cell 39, 223–232 (1984).
   PubMed Web of Science ®Google Scholar
• Reeves R, Wolffe AP. Substrate structure influences binding of the non-histone protein HMG-I(Y) to free nucleosomal DNA. Biochemistry 35, 5063–5074 (1996).
   PubMed Web of Science ®Google Scholar
• Reeves R, Leonard WJ, Nissen MS. 2000. Binding of HMG-I(Y) imparts architectural specificity to a positioned nucleosome on the promoter of the human interleukin-2 receptor alpha gene. Mol. Cell Biol. 20, 4666–4679 (2000).
   PubMed Web of Science ®Google Scholar
• Himes SR, Reeves R, Attema J, Nissen M, Li Y, Shannon MF. The role of high-mobility group I(Y) proteins in expression of IL-2 and T-cell proliferation. J. Immunol. 164, 3157–3168 (2000).
   PubMed Web of Science ®Google Scholar
• Attema JL, Reeves R, Murray V, Levichkin I, Temple MD, Tremethick DJ, Shannon MF. The human IL-2 gene promoter can assemble a positioned nucleosome that becomes remodeled upon T-cell activation. J. Immunol. 169, 2466–2476(2002).
   PubMed Web of Science ®Google Scholar
• Henderson A, Holloway A, Reevers R, Tremethick DJ. Recruitment of SWI/SNF to the human immunodeficiency virus type 1 promoter. Mol. Cell Biol. 24, 389–397 (2004).
   PubMed Web of Science ®Google Scholar
• Chiappetta G, Avantaggiato V, Visconti R et al. High level expression of the HMGI (Y) gene during embryonic development. Oncogene 13, 2439–2446 (1996).
   PubMed Web of Science ®Google Scholar
• Zhou G, Chen J, Lee S, Clark T, Rowley JD, Wang SM. The pattern of gene expression in human CD34+ stem/progenitor cells. Proc. Natl Acad. Sci. USA 98, 13966–13971 (2001).
   PubMed Web of Science ®Google Scholar
• Chou B-K, Mali P, Huang X et al. Efficient human iPS cell derivation by a non-integrating plasmid from blood cells with a unique epigenetic and gene expression signatures. Cell Res. 11, 518–529 (2011).
   Web of Science ®Google Scholar
• Karp JE, Smith BD, Resar LMS et al. Phase I and pharmacokinetic study of “hybrid” (bolus-infusion) flavopiridol administered followed in time sequence by cytosine arabinoside and mitoxantrone for adults with relapsed and refractory acute leukemias. Blood 117, 3302–3310 (2011).
   PubMed Web of Science ®Google Scholar
• Nelson DM, Joseph B, Hillion J, Segal J, Karp J, Resar LMS. Flavopiridol induces BCL-2 expression and represses oncogenic transcription factors in leukemic blasts from adults with refractory acute myeloid leukemia. Leuk. Lymphoma 52, 1999–2006 (2011).
   PubMed Web of Science ®Google Scholar
• Munoz J, Stange DE, Schepers AG et al. The Lgr5 intestinal stem cell signature: robust expression of proposed quiescent +4 markers. EMBO J. 31, 3079–3091 (2012).
   PubMed Web of Science ®Google Scholar
• Battista S, Pentimalli F, Baldassarre G.et al. Loss of HMGA1 gene function affects embryonic stem cell lympho-hematopoietic differentiation. FASEB J. 17, 1496–1498 (2003).
   Google Scholar
• Foti D, Chiefari E, Fedele M et al. Lack of the architectural factor HMGA1 causes insulin resistance and diabetes in humans and mice. Nat. Med. 11, 765–773 (2005).
   PubMed Web of Science ®Google Scholar
• Fedele M, Fidanza V, Battista S et al. Haploinsufficiency of the HMGA1 gene causes cardiac hypertrophy and myelo-lymphoproliferative disorders in mice. Cancer Res. 66, 2536–2543 (2006).
   PubMed Web of Science ®Google Scholar
• Xu Y, Sumter Felder T, Bhattacharya R. The HMG-I oncogene causes highly penetrant, metastatic lymphoid malignancy in transgenic mice and is overexpressed in human lymphoid malignancy. Cancer Res. 64, 3371–3375 (2004).
   Google Scholar
• Fedele M, Pentimalli F, Baldassarre G et al. Transgenic mice overexpressing the wild-type form of the HMGA1 gene develop mixed growth hormone/prolactin cell pituitary adenomas and natural killer cell lymphomas. Oncogene 24, 3427–3435 (2005).
   PubMed Web of Science ®Google Scholar
• Tesfaye A, Di Cello F, Hillion J et al. The High-Mobility Group A1 gene up-regulates Cyclooxygenase-2 expression in uterine tumorigenesis. Cancer Res. 67, 3998–4004 (2007).
   PubMed Web of Science ®Google Scholar
• Di Cello F, Dhara S, Hristov A et al. Inactivation of the Cdkn2a locus cooperates with HMGA1 to drive T-cell leukemogenesis. Leuk. Lymphoma 54(8), 1762–1768 (2013).
   PubMed Web of Science ®Google Scholar
• Somervaille TC, Matheny CJ, Spencer GJ et al. Hierarchical maintenance of MLL myeloid leukemia stem cells employs a transcriptional program shared with embryonic rather than adult stem cells. Cell Stem Cell 4, 129–140 (2009).
   PubMed Web of Science ®Google Scholar
• Wood LJ, Mukherjee M, Dolde CE et al. HMG-I/Y: a new c-Myc target gene and potential human oncogene. Mol. Cell Biol. 20, 5490–5502 (2000).
   PubMed Web of Science ®Google Scholar
• Wood LJ, Maher J, Bunton TE, Resar LMS. The oncogenic properties of the HMG-I gene family. Cancer Res. 60, 4256–4261 (2000).
   PubMed Web of Science ®Google Scholar
• Pomeroy SL, Tamayo P, Gaasenbeek M et al. Prediction of central nervous system embryonaltumour outcome based on gene expression. Nature 415, 436–442 (2002).
   PubMed Web of Science ®Google Scholar
• Takaha N, Resar LMS, Vindivich D, Coffey D. High mobility protein HMGI(Y) enhances tumor cell growth, invasion, and matrix metalloproteinase-2 expression in prostate cancer cells. Prostate 60, 160–167 (2004).
   PubMed Web of Science ®Google Scholar
• Hommura F, Katabami M, Leaner VD et al. HMG-I/Y is a cJun/AP-1 responsive gene and is necessary for cJun induced anchorage-independent growth. Mol. Cancer Res. 2, 303–314 (2004).
   Web of Science ®Google Scholar
• Shah S, Resar LMS. HMGA1 in Cancer: potential biomarker and therapeutic target. Histol. Histopath. 27, 567–579 (2012).
   PubMed Web of Science ®Google Scholar
• Roy S, Di Cello F, Kowalski J et al.. HMGA1 overexpression correlates with relapse in childhood B-lineage acute lymphoblastic leukemia. Leuk. Lymphoma 54(11), 2565–2567 (2013).
   Google Scholar
• Dolde CE, Mukherjee M, Cho C, Resar LMS. The role of HMG-I/Y in human breast cancer cells. Breast Cancer Res. Treat. 71, 181–191 (2002).
   PubMed Web of Science ®Google Scholar
• Hillion J, Wood LJ, Mukerjee M et al. Up-regulation of matrix metalloproteinase-2 by HMGA1 promotes transformation in undifferentiated, large cell human lung cancer. Mol Cancer Res. 7, 1803–1812 (2009).
   PubMed Web of Science ®Google Scholar
• Hillion J, Dhara S, Sumter TF et al. The HMGA1a-STAT3 axis: an “Achilles heel” for hematopoietic malignancies? Cancer Res. 68, 10121–10127 (2008).
   PubMed Web of Science ®Google Scholar
• Liau SS, Jazag A, Whang EE. HMGA1 is a determinant of cellular invasiveness and in vivo metastatic potential in pancreatic adenocarcinoma. Cancer Res. 66, 11613–11622 (2006).
   PubMed Web of Science ®Google Scholar
• Sarhadi VK, Wikman H, Salmenkivi K et al. Increased expression of high mobility group A proteins in lung cancer. J. Pathol. 209, 206–212 (2006).
   PubMed Web of Science ®Google Scholar
• Mani SA, Guo W, Liao M J et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133, 704–715 (2008).
   PubMed Web of Science ®Google Scholar
• Lim J, Thiery JP. Epithelial-mesenchymal transitions: insights from development. Development 139(19), 3471–3486 (2012).
   PubMed Web of Science ®Google Scholar
• Scheel C, Weinberg RA. Cancer stem cells and epithelial-mesenchymal transition: concepts and molecular links. Sem. Cancer Biol. 22, 396–401 (2012).
   PubMed Web of Science ®Google Scholar
• Dhar A, Hu J, Reeves R, Resar L, Colburn N. Dominant negative c-Jun (TAM67) target genes: HMGA1 is required for tumor promoter-induced transformation. Oncogene 23, 4466–4476 (2004).
   PubMed Web of Science ®Google Scholar
• Scala S, Portella G, Fedele M, Chiappetta G, Fusco A. Adenovirus-mediated suppression of HMGI(Y) protein synthesis as potential therapy of human malignant neoplasias. Proc. Natl Acad. Sci. USA 97, 4256–4261 (2000).
   PubMed Web of Science ®Google Scholar
• Foster LC, Wiesel P, Huggins GS et al. Role of activating protein-1 and high mobility group-I(Y) protein in the induction of CD44 gene expression by interleukin-1beta in vascular smooth muscle cells. FASEB J. 14, 368–378 (2000).
   PubMed Web of Science ®Google Scholar
• Beckerbauer L, Tepe JJ, Cullison Jet al.. FR900482 class of anti-tumor drugs cross-links oncoprotein HMG I/Y to DNA in vivo. Chem. Biol. 7, 805–812 (2000).
   Google Scholar
• Beckerbauer L, Tepe JJ, Eastman RAet al.. Differential effects of FR900482 and FK317 on apoptosis, IL-2 gene expression, and induction of vascular leak syndrome. Chem. Biol. 9, 427–441 (2002).
   Google Scholar
• Ma W, Oriz-Quintero B, Rangel R, et al. Innate activation of inflammatory gene networks, alveolar destruction and neonatal death in AKNA deficient mice. Cell Res. 21, 1564–1577 (2011).
   PubMed Web of Science ®Google Scholar
• Moliterno A, Resar L. AKNA : another AT-hook transcription factor hooking up with inflammation. Cell Res. 21, 1528–1530 (2011).
   Google Scholar
• Di Cello F, Hillion J, Aderinto A et al. COX-2 inhibitors block uterine tumorigenesis in HMGA1a transgenic mice and human uterine cancer xenografts. Mol. Cancer Ther. 7(7), 2090–2095 (2008).
   PubMed Web of Science ®Google Scholar
• Hillion J, Di Cello F, Belton Aet al.. Nanoparticle delivery of inhibitory STAT3 GQ-oligonucleotides blocks tumor growth in an HMGA1 transgenic model of T-cell leukemia. Leuk. Lymphoma doi:10.3109/10428194.2013.821202 (2013) (Epub ahead of print).
   Google Scholar
• Boylan NJ, Suk JS, Lai SK et al. Highly compacted DNA nanoparticles with low MW PEG coatings: In vitro, ex vivo and in vivo evaluation. J. Control. Release 157, 72–79 (2012).
   PubMed Web of Science ®Google Scholar
• Wang AZ, Langer R, Farokhzad OC. Nanoparticle delivery of cancer drugs. Annu. Rev. Med. 63, 185–198 (2012).
   PubMed Web of Science ®Google Scholar
• Pramanik D, Campbell NR, Karikari C et al. Resititution of tumor suppressor microRNAs using a systemic nanovector inhibits pancreatic cancer growth in mice. Mol. Cancer Ther. 10, 1470–1480 (2011).
   PubMed Web of Science ®Google Scholar
• Mussnich P, D’Angelo D, Leone V, Croce CM, Fusco A. The high mobility group A proteins contribute to thyroid cell transformation by regulating miR-603 and miR-10b expression. Mol. Oncol. 7, 531–542 (2013).
   PubMed Web of Science ®Google Scholar
• Resar LMS, Brodsky RA. “Let”-ing go with clonal expansion? Blood 117, 5788–5790 (2011).
   Google Scholar